Anti-Neoplastic Agents Market 2024-2033: Technological Advancements, Competitive Landscape and Strategies

Spread the love

The anti-neoplastic agents global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Anti-Neoplastic Agents Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The anti-neoplastic agents market size has grown rapidly in recent years. It will grow from $118.03 billion in 2023 to $130.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.

The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $184.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

Scope Of Anti-Neoplastic Agents Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Anti-Neoplastic Agents Market Overview

Market Drivers –
The increasing number of cancer cases is expected to propel the growth of the antineoplastic agent market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their normal boundaries and either spread to other organs or invade neighboring body parts. Antineoplastic agents play an essential role in cancer treatment by inhibiting cancer cell growth and division through various mechanisms, including DNA (Deoxyribonucleic acid) damage, cell cycle disruption and interference with crucial cellular pathways. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase from 1.8 million new cancer cases diagnosed in 2020. Further, 609,820 cancer-related deaths are anticipated in 2023, an increase from 606,520 in 2020. Therefore, the increasing number of cancer cases is driving the growth of the antineoplastic agent market.

Market Trends –
Major companies operating in the anti-neoplastic agent market are focused on developing clinical practices to sustain their position in the market. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical corporation, announced the Food and Drug Administration’s (FDA) approval of Pluvicto, a first targeted radioligand therapy for the treatment of progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). It is recommended to provide 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses or until disease progression or intolerable toxicity, whichever comes first. Based on PSMA expression in tumors, patients with previously treated mCRPC should be chosen for treatment with Pluvicto utilizing Locametz or another authorized PSMA-11 imaging agent.

The anti-neoplastic agents market covered in this report is segmented –

1) By Type: Alkylating Agents; Antimetabolites; Hormones And Antagonists; Miscellaneous
2) By Disease Type: Gastrointestinal Cancer; Prostate Cancer; Lung Cancer; Breast Cancer; Other Disease Types
3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers

Get an inside scoop of the anti-neoplastic agents market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Regional Insights –
North America was the largest region in the anti-neoplastic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies –
Major players in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Table of Contents
1. Executive Summary
2. Anti-Neoplastic Agents Market Report Structure
3. Anti-Neoplastic Agents Market Trends And Strategies
4. Anti-Neoplastic Agents Market – Macro Economic Scenario
5. Anti-Neoplastic Agents Market Size And Growth
…..
27. Anti-Neoplastic Agents Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedInhttps://in.linkedin.com/company/the-business-research-company
Twitterhttps://twitter.com/tbrc_info
Facebookhttps://www.facebook.com/TheBusinessResearchCompany
YouTubehttps://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Bloghttps://blog.tbrc.info/
Healthcare Bloghttps://healthcareresearchreports.com/
Global Market Modelhttps://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →